Enclomiphene Citrate for Secondary Hypogonadism: Off-Label Dosing Protocol

What Is Enclomiphene Citrate and Why Is It Used Off-Label?

Enclomiphene citrate is the pharmacologically active trans-isomer of clomiphene citrate, the mixed-isomer SERM that has been prescribed for decades in both male and female reproductive medicine. While clomiphene (Clomid) contains roughly 62% enclomiphene and 38% zuclomiphene, the isolated enclomiphene compound was developed to provide estrogen receptor antagonism at the hypothalamus without the estrogenic agonist effects attributed to the zu-isomer 1.

The drug reached Phase III clinical trials under the brand name Androxal for the treatment of secondary hypogonadism in overweight men, but the FDA issued a Complete Response Letter in 2015 requesting additional studies. The manufacturer did not pursue further approval. As of 2026, enclomiphene citrate holds no FDA-approved indication for any condition 2.

Compounding pharmacies now produce enclomiphene citrate capsules, and prescribing clinicians use it off-label specifically because it raises testosterone through the body's own HPG axis rather than shutting it down. For men who want to treat low testosterone symptoms while keeping fertility intact, this pharmacologic profile is appealing. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that SERMs represent an alternative to exogenous testosterone in men desiring fertility preservation, though the guideline references clomiphene rather than isolated enclomiphene by name 3.

Mechanism of Action: How Enclomiphene Restores Testosterone

Enclomiphene blocks estrogen receptor alpha (ERα) in the hypothalamus, removing the negative feedback that estradiol normally exerts on gonadotropin-releasing hormone (GnRH) pulse frequency. The downstream result is increased pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then stimulates Leydig cells in the testes to produce testosterone, while FSH supports Sertoli cell function and spermatogenesis 1.

This is the opposite of what exogenous testosterone does. Injected or topical testosterone suppresses GnRH through negative feedback, causing LH and FSH to fall. Sperm production declines. Testicular volume may shrink. Enclomiphene avoids all of this by working upstream of the testes.

A 2014 randomized trial (ZA-304, N=124) compared enclomiphene 12.5 mg and 25 mg to topical testosterone gel 1.62% over 16 weeks. Both enclomiphene doses raised total testosterone into the normal range (above 300 ng/dL) while simultaneously increasing or maintaining LH and sperm concentrations. The testosterone gel group showed suppressed LH and reduced sperm counts, as expected 4.

Clinical Trial Evidence for Enclomiphene in Secondary Hypogonadism

Three Phase III trials form the primary evidence base. These were conducted in men aged 18 to 65 with secondary hypogonadism defined as morning total testosterone below 300 ng/dL on two occasions, with LH levels that were not elevated (ruling out primary testicular failure).

ZA-301 (N=253): This 12-week, randomized, placebo-controlled trial assigned men to enclomiphene 12.5 mg, enclomiphene 25 mg, or placebo. The 12.5 mg group achieved mean morning testosterone of 454 ng/dL compared to 364 ng/dL with placebo. The 25 mg arm reached 479 ng/dL. Both doses significantly increased LH and FSH 1.

ZA-303 (N=166): In this active-comparator study, enclomiphene 12.5 mg was compared against topical testosterone gel. Both groups achieved normal testosterone levels. Sperm concentrations in the enclomiphene arm increased by a median of 3.3 million/mL, while the testosterone gel group saw a median decrease of 7.7 million/mL at 16 weeks 5.

ZA-304 (N=124): This trial confirmed the sperm-preserving advantage of enclomiphene across both dose levels versus topical testosterone, with gonadotropin levels rising in the enclomiphene groups and falling in the gel group 4.

A pooled analysis published in BJU International in 2016 reported that 79% of men on enclomiphene 12.5 mg achieved a morning testosterone above 300 ng/dL, compared to 39% on placebo 6. The magnitude of testosterone increase was dose-dependent, and responses were generally seen within the first 2 to 4 weeks.

"Enclomiphene citrate consistently restored testosterone and gonadotropin levels in men with secondary hypogonadism while preserving or improving sperm parameters," wrote Wiehle et al. in their 2014 analysis of the ZA-304 data 4.

Off-Label Dosing Protocol

No FDA-approved labeling exists, so dosing protocols are derived from the Phase III trial regimens and published clinical experience. The following represents the most commonly reported approach in the peer-reviewed literature and specialty clinic practice.

Starting dose: 12.5 mg orally once daily, taken in the morning. This was the lower dose tested across all three Phase III studies and produced clinically meaningful testosterone elevation with a favorable side effect profile 1.

Dose adjustment: If total testosterone remains below the target range (typically 450 to 700 ng/dL) after 4 to 6 weeks, the dose may be increased to 25 mg daily. The ZA-301 trial showed a modest incremental benefit at 25 mg over 12.5 mg (479 vs. 454 ng/dL mean total T), so some clinicians start at the higher dose in men with baseline testosterone below 200 ng/dL 1.

Alternate-day dosing: Some clinicians prescribe 25 mg every other day as a middle-ground regimen, though this schedule was not formally studied in the Phase III program. No published RCT supports this approach specifically.

Duration: The longest published trial ran 16 weeks. Observational reports describe continuous use beyond 12 months, but long-term safety data from controlled studies are not available. The Endocrine Society guideline on testosterone therapy recommends reassessing any hormonal treatment at 3 to 6 month intervals 3.

Administration: Enclomiphene is taken with or without food. No significant food-drug interactions have been identified in the published pharmacokinetic data.

Monitoring and Lab Work

Baseline labs before initiating enclomiphene should include total testosterone (drawn before 10 AM), free testosterone, LH, FSH, estradiol, complete blood count, comprehensive metabolic panel, and a lipid panel. A semen analysis is appropriate if fertility preservation is a stated goal 3.

Follow-up labs at 4 to 6 weeks should assess total testosterone and estradiol. Because enclomiphene blocks hypothalamic estrogen feedback, estradiol levels may rise as testosterone increases and undergoes aromatization. An estradiol level above 50 pg/mL may warrant discussion about adding a low-dose aromatase inhibitor, though this adds a second off-label medication and should be approached carefully 7.

Ongoing monitoring every 3 to 6 months should include total testosterone, LH, FSH, estradiol, hematocrit (to screen for polycythemia, though this risk is lower than with exogenous testosterone), and PSA in men over 40. A rising LH paired with a falling testosterone response over time could indicate developing primary testicular insufficiency, which would make enclomiphene less effective.

"We recommend monitoring serum testosterone 3 to 6 months after initiating testosterone therapy and then annually," states the Endocrine Society guideline, a schedule that applies equally to SERM-based approaches to hypogonadism 3.

Enclomiphene vs. Clomiphene (Clomid): Why the Isomer Matters

Standard clomiphene citrate (Clomid) has been used off-label for male hypogonadism for decades with good testosterone outcomes. A 2015 meta-analysis of nine studies (N=536 men) found that clomiphene citrate raised mean testosterone from 228 ng/dL to 474 ng/dL in hypogonadal men 8.

The problem is the zuclomiphene isomer. Zuclomiphene acts as a partial estrogen agonist with a half-life of approximately 2 weeks, compared to roughly 10 hours for enclomiphene. It accumulates with chronic dosing and may produce estrogenic side effects including gynecomastia, mood changes, and visual disturbances 9. Some men on clomiphene report feeling worse despite improved testosterone numbers, and the accumulated estrogenic activity of zuclomiphene is a plausible explanation.

Enclomiphene was developed specifically to capture the anti-estrogenic, gonadotropin-stimulating properties of the trans-isomer without the agonist baggage of the zu-isomer. In the ZA-303 trial, enclomiphene produced similar testosterone elevation to clomiphene with a cleaner pharmacokinetic profile and faster washout 5.

The practical trade-off: clomiphene is FDA-approved (for female ovulation induction), inexpensive, and available at any pharmacy. Enclomiphene must be obtained from compounding pharmacies, costs more, and lacks standardized quality assurance across compounders.

Enclomiphene vs. TRT: Choosing the Right Approach

The decision between enclomiphene and testosterone replacement depends on two questions. Does the patient want to preserve fertility? Does the patient have secondary (hypothalamic-pituitary) hypogonadism rather than primary (testicular) failure?

If both answers are yes, enclomiphene is a reasonable first-line trial. Exogenous testosterone will suppress spermatogenesis, and recovery after discontinuation can take 6 to 12 months or longer. A 2019 study published in Fertility and Sterility found that 10% of men who used exogenous testosterone for more than 2 years had persistent azoospermia at 12 months after stopping 10.

If the patient has primary hypogonadism with elevated LH, enclomiphene will not work. The testes are already receiving maximal gonadotropin stimulation; adding more LH drive cannot overcome Leydig cell failure.

If fertility is not a concern and the patient has documented hypogonadism with significant symptoms, testosterone replacement may produce more predictable and higher testosterone levels, particularly in men with severe deficiency (total T below 150 ng/dL). The ZA-301 trial achieved mean levels in the 450 to 480 ng/dL range with enclomiphene, while injectable testosterone cypionate 200 mg every 2 weeks typically produces peak levels of 800 to 1,000 ng/dL 3.

Side Effects and Safety Considerations

In the pooled Phase III data, enclomiphene was well tolerated. The most common adverse events at 12.5 mg were headache (4.8%), nausea (3.2%), and hot flashes (2.1%). Discontinuation rates due to adverse events were similar between enclomiphene and placebo groups 1.

Visual disturbances, a known concern with mixed clomiphene citrate, were not reported at clinically significant rates in the enclomiphene trials. This supports the hypothesis that visual side effects are driven by zuclomiphene's estrogenic agonism rather than by estrogen receptor antagonism itself 9.

Potential risks that lack adequate long-term data include:

• Venous thromboembolism (VTE): SERMs as a class carry a small VTE risk. Tamoxifen increases VTE incidence by approximately 2-fold in breast cancer populations. Whether enclomiphene carries similar risk in younger men at lower doses is unknown 11.
• Bone mineral density effects: Estrogen receptor blockade at bone could theoretically reduce bone density over years of use. No long-term bone data exist for enclomiphene in men.
• Compounding variability: Without FDA-approved manufacturing standards, potency and purity may vary between compounding pharmacies. The FDA has issued warnings about risks associated with compounded medications generally 2.

Who Is a Good Candidate?

The ideal candidate for off-label enclomiphene is a man with confirmed secondary hypogonadism (low testosterone with low or inappropriately normal LH), who wants to preserve fertility or avoid HPG axis suppression, and who has no contraindications to SERM therapy.

Contraindications include a personal history of venous thromboembolism, known hypersensitivity to clomiphene or related compounds, and active liver disease. Men with primary hypogonadism, hyperprolactinemia, or pituitary tumors should not be started on enclomiphene without further endocrine workup, since these conditions require different treatment 3.

Men who have previously responded well to clomiphene citrate but experienced estrogenic side effects (gynecomastia, mood instability, or visual changes) are particularly good candidates for a trial of isolated enclomiphene.

Compounding, Cost, and Access

Because enclomiphene citrate has no FDA-approved formulation, it is available only through compounding pharmacies in the United States. Prescribers write for enclomiphene citrate capsules, typically in 12.5 mg or 25 mg strengths. Cost ranges from $30 to $90 per month depending on the pharmacy, dose, and whether the patient pays cash or uses a membership program 2.

Insurance coverage is unlikely. Compounded medications are rarely covered by pharmacy benefit plans, and the off-label status adds another barrier.

Patients should be counseled to use 503B outsourcing facilities that operate under FDA oversight rather than traditional 503A compounding pharmacies, when possible. 503B facilities must comply with current Good Manufacturing Practice (cGMP) standards, which provides greater assurance of dose accuracy and sterility 12.

Men considering enclomiphene from online peptide or research chemical vendors should be strongly discouraged. These products are not manufactured for human consumption, carry no quality assurance, and using them bypasses the medical supervision that off-label prescribing requires.

The Regulatory Horizon

The FDA's 2015 rejection of Androxal was not based on safety or efficacy concerns alone. The Complete Response Letter cited analytical chemistry issues with the drug product and requested additional data, according to public filings by the sponsor, Repros Therapeutics. The company was later acquired, and no new FDA application has been submitted 2.

Given the current regulatory pathway, FDA approval for enclomiphene citrate in secondary hypogonadism appears unlikely in the near term without a new sponsor willing to fund additional trials. The compounding market has filled the gap, but this means patients and prescribers must accept the limitations of off-label use, compounding variability, and an incomplete long-term safety record.

Baseline morning testosterone should be confirmed on at least two separate draws before starting therapy, LH and FSH must be checked to confirm secondary etiology, and follow-up labs at 4 to 6 weeks should verify both a testosterone response above 300 ng/dL and an estradiol level below 50 pg/mL 3.